HK1163068A1 - New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins - Google Patents

New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins

Info

Publication number
HK1163068A1
HK1163068A1 HK12103460.1A HK12103460A HK1163068A1 HK 1163068 A1 HK1163068 A1 HK 1163068A1 HK 12103460 A HK12103460 A HK 12103460A HK 1163068 A1 HK1163068 A1 HK 1163068A1
Authority
HK
Hong Kong
Prior art keywords
macrolide
ophthalmic
topical
oral
aqueous solutions
Prior art date
Application number
HK12103460.1A
Other languages
English (en)
Chinese (zh)
Inventor
Alberto Mangia
Paride Grisenti
Riccardo Monti
Elahi Shahrzad Reza
Elisa Verza
Original Assignee
Euticals Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euticals Spa filed Critical Euticals Spa
Publication of HK1163068A1 publication Critical patent/HK1163068A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12103460.1A 2010-07-01 2012-04-10 New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins HK1163068A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2010A001212A IT1400977B1 (it) 2010-07-01 2010-07-01 Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.

Publications (1)

Publication Number Publication Date
HK1163068A1 true HK1163068A1 (en) 2012-09-07

Family

ID=43034339

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103460.1A HK1163068A1 (en) 2010-07-01 2012-04-10 New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins

Country Status (8)

Country Link
US (1) US9169269B2 (de)
EP (1) EP2402350B1 (de)
JP (1) JP5856769B2 (de)
BR (1) BRPI1103562A2 (de)
ES (1) ES2534989T3 (de)
HK (1) HK1163068A1 (de)
HU (1) HUE025154T2 (de)
IT (1) IT1400977B1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
JP7376361B2 (ja) 2017-03-07 2023-11-08 エフ． ホフマン－ラ ロシュ アーゲー 免疫調節マクロライドのための安定な配合物
CN107213470B (zh) * 2017-06-01 2020-05-19 中牧南京动物药业有限公司 酒石酸泰万菌素可溶性粉及其制备方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2023213731A1 (en) 2022-05-02 2023-11-09 Roche Diagnostics Gmbh Hemolysis and derivatization reagents and methods for determining lactone analytes
WO2024074699A1 (en) 2022-10-07 2024-04-11 Oculis Operations Sarl Eye drop microsuspensions of mtor inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US7655442B2 (en) * 2004-01-29 2010-02-02 Eisai R&D Management Co., Ltd. Method for stabilizing macrolide compounds
DE602005024012D1 (de) 2004-08-27 2010-11-18 Cordis Corp Lösungsmittelfreies amorphes rapamycin
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
EP2135601A1 (de) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilisierung amorpher Arzneimittel über schwammähnliche Trägermatrizen

Also Published As

Publication number Publication date
EP2402350A1 (de) 2012-01-04
JP5856769B2 (ja) 2016-02-10
ES2534989T3 (es) 2015-05-04
BRPI1103562A2 (pt) 2015-07-28
JP2012031160A (ja) 2012-02-16
ITMI20101212A1 (it) 2012-01-02
IT1400977B1 (it) 2013-07-05
US20120053198A1 (en) 2012-03-01
HUE025154T2 (hu) 2016-03-29
EP2402350B1 (de) 2015-01-28
US9169269B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
HK1163068A1 (en) New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins
NL301021I1 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300909I2 (nl) Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
AP2010005490A0 (en) Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin.
NL300971I2 (nl) Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
HRP20160953T1 (hr) Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol
EP2604612A4 (de) C-aryl-glucosidderivat, verfahren zu seiner herstellung und pharmazeutische verwendung davon
HK1161878A1 (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof
IL222930A0 (en) Chlorotoxin variants, conjugates and methods for their use
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
HK1145631A1 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
IL225227B (en) A complex containing cyclodextrin and fulvestrant, its uses and methods for its preparation
EP2763693A4 (de) Blutgerinnungsfaktor sowie derivate, konjugate und komplexe damit sowie verwendung davon
EP2510825B8 (de) Drehanhängekupplung
WO2012131378A3 (en) Pharmaceutical preparation comprising alpha emitting radionuclide
HK1249848A1 (zh) 親脂性物質的水溶液，特別是藥物物質溶液
PL2480540T3 (pl) Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne
EP2331555B8 (de) Ferrocenderivate mit antineoplastischer Activität